Captrust Financial Advisors Jounce Therapeutics, Inc. Transaction History

Captrust Financial Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.9 - $1.85 $13,194 - $27,121	14,660 New	14,660 $27,000
Q3 2022 Nov 16, 2022	BUY	$2.73 - $4.92 $35,760 - $64,447	13,099 Added 58.22%	35,599 $83,000
Q2 2022 Aug 16, 2022	SELL	$2.8 - $7.67 $5,600 - $15,340	-2,000 Reduced 8.16%	22,500 $68,000
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $19,740 - $31,980	3,000 Added 13.95%	24,500 $167,000
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $67,300 - $138,700	10,000 Added 86.96%	21,500 $221,000
Q4 2020 Feb 16, 2021	BUY	$6.37 - $10.33 $3,185 - $5,165	500 Added 4.55%	11,500 $80,000
Q2 2020 Aug 14, 2020	BUY	$4.17 - $7.58 $45,870 - $83,380	11,000 New	11,000 $73,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.